Blue Jet Healthcare (NSE:BLUEJET) filed its 58th Annual General Meeting notice with exchanges on 18 August 2026, scheduling the meeting for 21 September 2026 at 11:00 AM IST via video conferencing. The agenda includes declaration of a final dividend of Rs 1.20 per equity share for FY2025-26 and re-appointment of key managerial personnel.
Key Highlights
- The 58th AGM will be held on Monday, 21 September 2026, at 11:00 AM IST through video conferencing or other audio-visual means, with the deemed venue being the company's registered office in Sanpada, Mumbai.
- A final dividend of Rs 1.20 per equity share for FY2025-26 has been recommended, with a record date of Monday, 14 September 2026, for determining shareholder eligibility.
- Shareholders will vote on the re-appointment of Mr. Akshay Bansarilal Arora (DIN: 00105637) as Whole-Time Director and Executive Chairman for five years from 13 April 2027 to 12 April 2032.
- M/s KKC & Associates LLP (ICAI Firm Registration No. 117366W/W-100018) is proposed for re-appointment as statutory auditors for a second term of five consecutive years through the 63rd AGM.
About the Company
Blue Jet Healthcare (NSE:BLUEJET) is a Mumbai-headquartered pharmaceutical and healthcare company operating in the Pharma and Healthcare sector. The company manufactures active pharmaceutical ingredients, contrast media intermediates, and specialty chemicals, supplying global innovator pharmaceutical companies. It is listed on both NSE and BSE (Scrip Code: 544009) and maintains its registered office at Bhumiraj Costarica, Sector 18, Sanpada, Mumbai.
Announcement in Detail
The AGM notice, filed pursuant to Regulation 34(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, covers six agenda items. Ordinary business includes adoption of audited standalone financial statements for FY2025-26, declaration of the Rs 1.20 per share final dividend, and re-appointment of Mr. Naresh Suryakant Shah (DIN: 03073963), who retires by rotation under Section 152(6) of the Companies Act, 2013.
Special business includes re-appointment of Mr. Shiven Akshay Arora (DIN: 07351133) as Managing Director for five years from 13 April 2027 to 12 April 2032, not liable to retire by rotation. Both executive re-appointments require shareholder approval via special resolution, and the board is authorised to alter remuneration terms within limits prescribed under the Companies Act, 2013.
Impact on Investors
Investors will note that the final dividend of Rs 1.20 per equity share will be paid within thirty days of AGM approval, provided shareholders update KYC details with their depository participants to avoid delays. The record date for dividend eligibility is 14 September 2026, as disclosed in the filing.
The disclosed terms indicate that the re-appointments of both executive directors carry provisions permitting remuneration exceeding the limits under Regulation 17(6)(e) of SEBI LODR, subject to shareholder consent via special resolution. Shareholders will observe that these resolutions are notices of upcoming votes, not concluded decisions, and outcomes will be known only after 21 September 2026.
Sector / Market Context
India's pharmaceutical sector remains a significant contributor to global drug supply, with the country being among the largest exporters of generic medicines, according to the Pharmaceuticals Export Promotion Council of India. Contrast media intermediates, a key product area for Blue Jet Healthcare, serve demand from diagnostic imaging, a segment that continues to grow with healthcare infrastructure expansion across developed markets.